Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Tafinlar

This page shows the latest Tafinlar news and features for those working in and with pharma, biotech and healthcare.

Rival Opdivo rejected, Novartis combo gets NICE green light in adjuvant melanoma

Rival Opdivo rejected, Novartis combo gets NICE green light in adjuvant melanoma

Proactive adjuvant treatment could extend melanoma patient lives. England’s cost effectiveness watchdog NICE has recommended the use of Novartis’ Tafinlar (dabrafenib and Mekinst (trametinib) combination in melanoma. ... This is good news for

Latest news

  • Novartis wins key adjuvant Taf/Mek approval in Europe Novartis wins key adjuvant Taf/Mek approval in Europe

    Ex-GSK duo on course for first blockbuster year. Novartis’ cancer combination Tafinlar and Mekinist has been approved by the EMA for adjuvant treatment of advanced melanoma in order to prevent ... Tafinlar… particularly given the competition that of

  • Novartis scores but Roche misses in melanoma trials Novartis scores but Roche misses in melanoma trials

    Phase III trial combo success for Tafinlar/Mekinist “unprecedented”. A phase III trial of Novartis Tafinlar and Mekinist has confirmed the potential of the pair in the post-surgical treatment of ... The combination of Novartis BRAF inhibitor Tafinlar

  • Novartis gets lung cancer OK for Tafinlar/Mekinist combo Novartis gets lung cancer OK for Tafinlar/Mekinist combo

    The FDA has granted priority review to Tafinlar/Mekinist for the treatment of BRAF mutant NSCLC with disease progression on or after platinum-containing chemotherapy. ... Novartis acquired Tafinlar and Mekinist as part of its asset-swap deal with

  • J&J gets CHMP backing for broader Darzalex use J&J gets CHMP backing for broader Darzalex use

    CHMP round-up. At its meeting last week the CHMP also gave its blessing to the combination of Novartis' Tafinlar (dabrafenib) and Mekinist (trametinib) in BRAF-positive non-small cell lung

  • The UK's new Cancer Drugs Fund The UK's new Cancer Drugs Fund

    Gaining the greenlight were Novartis' Zykadia (ceritinib) for lung cancer and melanoma combination Tafinlar (dabrafenib) and Mekinist (trametinib), and Servier's Lonsurf (trifluridine/tipiracil HCl) for bowel cancer.

More from news
Approximately 10 fully matching, plus 35 partially matching documents found.

Latest Intelligence

  • Pharma deals during April 2014 Pharma deals during April 2014

    GSK's recently approved MEK inhibitor Mekinist and BRAF inhibitor Tafinlar will position Novartis to become a leader in the potential blockbuster market for metastatic melanoma, neglected by their current portfolio.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Quick links

Infographics

Multimedia